Eli Lilly and Company $LLY Stock Acquired by Profund Advisors LLC

Key Points

• Profund Advisors increased its Eli Lilly stake by 11.6% in the third quarter, bringing its holdings to 10,648 shares valued at approximately $12.3 million. Institutional investors collectively own 82.53% of the company.
• Lilly reported strong quarterly results, with revenue up 38.6% year over year to $24.4 billion and EPS of $7.48, exceeding estimates. Robust demand for Mounjaro and Zepbound prompted the company to raise its full-year outlook.
• Analyst sentiment remains favorable but risks persist: Lilly has a “Moderate Buy” consensus rating and an average price target of $1,404.14, while investors are watching for pricing pressure, slower growth, high valuation and continued insider selling.

Profund Advisors LLC increased its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 11.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 10,648 shares of the company's stock after purchasing an additional 1,110 shares during the period. Profund Advisors LLC's holdings in Eli Lilly and Company were worth $12,321,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. ProShare Advisors LLC raised its stake in shares of Eli Lilly and Company by 4.0% in the 3rd quarter. ProShare Advisors LLC now owns 134,385 shares of the company's stock valued at $155,494,000 after purchasing an additional 5,181 shares during the period. Vise Technologies Inc. grew its position in Eli Lilly and Company by 19.9% in the third quarter. Vise Technologies Inc. now owns 41,180 shares of the company's stock valued at $47,648,000 after purchasing an additional 6,827 shares in the last quarter. Investment Partners LTD. increased its stake in Eli Lilly and Company by 28.6% in the 3rd quarter. Investment Partners LTD. now owns 7,314 shares of the company's stock valued at $8,463,000 after buying an additional 1,627 shares during the last quarter. Intrua Financial LLC increased its stake in Eli Lilly and Company by 0.6% in the 3rd quarter. Intrua Financial LLC now owns 2,257 shares of the company's stock valued at $2,612,000 after buying an additional 13 shares during the last quarter. Finally, BNB Wealth Management LLC increased its stake in Eli Lilly and Company by 4.1% in the 3rd quarter. BNB Wealth Management LLC now owns 641 shares of the company's stock valued at $741,000 after buying an additional 25 shares during the last quarter. Institutional investors own 82.53% of the company's stock.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Another strong quarter and higher guidance: Third-quarter revenue rose roughly 39% year over year to $24.4 billion, beating expectations, while adjusted EPS also exceeded estimates. Strong demand for Mounjaro and Zepbound led Lilly to raise its full-year outlook. Eli Lilly Just Delivered Another Blowout Quarter
• Positive Sentiment: Analyst price-target increases: Cantor Fitzgerald raised its target to $1,600 and maintained an “overweight” rating. Other firms, including JPMorgan, also boosted targets, reflecting continued confidence in Lilly’s earnings outlook. Cantor Fitzgerald price target
• Neutral Sentiment: Commercial reorganization: Lilly is combining its U.S. and international commercial operations into one division. The move could improve coordination and execution globally, but its financial effect is not yet clear. Lilly combines commercial divisions
• Negative Sentiment: Pricing and growth concerns: Medicare’s GLP-1 Bridge program and lower realized drug prices may pressure revenue and margins. Analysts also warn that growth could moderate after exceptionally strong results, while one-time revenue benefits may not recur. Lilly’s First Full Medicare Quarter
• Negative Sentiment: High expectations and concentration risk: With about two-thirds of revenue tied to its leading GLP-1 medicines and the shares trading at a premium valuation, investors may be taking profits and demanding evidence that rapid growth can continue. Eli Lilly: Softer Growth Ahead

Wall Street Analysts Forecast Growth

LLY has been the topic of several analyst reports. BMO Capital Markets reissued an "outperform" rating and set a $1,650.00 price target on shares of Eli Lilly and Company in a research report on Friday. Berenberg Bank upgraded Eli Lilly and Company from a "hold" rating to a "buy" rating and set a $1,400.00 price objective for the company in a report on Tuesday, September 15th. TD Cowen reaffirmed a "buy" rating and issued a $1,250.00 target price on shares of Eli Lilly and Company in a research report on Tuesday, September 22nd. Wells Fargo & Company upped their target price on Eli Lilly and Company from $1,330.00 to $1,500.00 and gave the stock an "overweight" rating in a report on Friday. Finally, The Goldman Sachs Group restated a "buy" rating and issued a $1,413.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, October 20th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $1,404.14.

Insider Buying and Selling

In related news, CAO Donald Zakrowski sold 2,000 shares of the company's stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the transaction, the chief accounting officer owned 1,526 shares in the company, valued at approximately $1,808,325.26. This represents a 56.72% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the transaction, the executive vice president directly owned 11,875 shares in the company, valued at approximately $14,131,250. This represents a 29.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 13,500 shares of company stock valued at $15,958,170. Company insiders own 0.14% of the company's stock.

Eli Lilly and Company Trading Down 0.4%

Shares of Eli Lilly and Company stock opened at $1,412.06 on Tuesday. The business has a fifty day simple moving average of $1,200.81 and a two-hundred day simple moving average of $1,094.25. Eli Lilly and Company has a 1 year low of $850.51 and a 1 year high of $1,449.68. The company has a market capitalization of $1.33 trillion, a price-to-earnings ratio of 45.83, a P/E/G ratio of 1.73 and a beta of 0.46. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, October 29th. The company reported $7.48 EPS for the quarter, topping analysts' consensus estimates of $5.71 by $1.77. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The firm had revenue of $24.40 billion during the quarter, compared to analysts' expectations of $22.58 billion. During the same period in the previous year, the business posted $7.02 earnings per share. The company's revenue for the quarter was up 38.6% compared to the same quarter last year. Research analysts forecast that Eli Lilly and Company will post 35.18 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, November 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. Eli Lilly and Company's payout ratio is presently 22.46%.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company's portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.